VolitionRx Q2 FY26 operating loss narrows 34% to $4.2 million; operating expenses fall 32% on year

Reuters2026/08/13 20:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VolitionRx Q2 2026 revenue was USD 0.4 million, roughly flat versus the year-earlier quarter.
Operating loss narrowed 34% to USD 4.2 million; operating expenses fell 32% on a cost-reduction program.
Net cash used in operating activities decreased 18% to USD 5.2 million.
First-half 2026 revenue more than doubled to USD 1.4 million, up 112% from the prior-year period.
Management cited talks with over a dozen diagnostics groups on licensing; highlighted Sysmex collaboration and a potential USD 5 million feline milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131610PR_NEWS_USPR_____LN25869) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VolitionRx Q2 FY26 operating loss narrows 34% to $4.2 million; operating expenses fall 32% on year

You may also like

Crypto prices